Entos Pharmaceuticals is a clinical-stage biotech company developing genetic medicines with its Fusogenix PLV drug delivery platform.
Entos Pharmaceuticals's investors include National Research Council of Canada Industrial Research Assistance Program, UK Research and Innovation, California Institute for Regenerative Medicine, CureDuchenne Ventures.
Entos Pharmaceuticals is headquartered in Edmonton, Canada.
Entos Pharmaceuticals is a clinical-stage biotech company developing genetic medicines with its Fusogenix PLV drug delivery platform.
Entos Pharmaceuticals is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Entos Pharmaceuticals — Funding & Investors." VCBacked, January 6, 2026, https://www.vcbacked.co/company/entos-pharmaceuticals. Accessed August 1, 2026.
VCBacked. (2026). Entos Pharmaceuticals — Funding & Investors. Retrieved August 1, 2026, from https://www.vcbacked.co/company/entos-pharmaceuticals
{{cite web |title=Entos Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/entos-pharmaceuticals |website=VCBacked |access-date=August 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated